Welcome to our dedicated page for Journey Medical news (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical stock.
Journey Medical Corp (DERM) is a commercial-stage pharmaceutical leader specializing in dermatology treatments. This page aggregates official announcements and verified updates about DERM's prescription drug developments, financial performance, and regulatory progress.
Find categorized press releases covering FDA approvals, clinical trial results, partnership agreements, and earnings disclosures. Investors gain streamlined access to strategic updates impacting DERM's position in the $7.3B U.S. dermatology pharmaceuticals market.
Key resources include product launch timelines, research collaboration details, and analysis of DERM's branded/generic medication portfolio. Content is rigorously curated to support informed decision-making without promotional bias.
Bookmark this page for efficient tracking of DERM's advancements in treating acne, rosacea, and other skin conditions through FDA-cleared therapies.
Journey Medical (Nasdaq: DERM) reported Q3 2025 net revenues of $17.6 million, a 21% year-over-year increase driven by the U.S. commercial launch of Emrosi. Emrosi generated $4.9 million in net sales and prescriptions rose 146% sequentially versus Q2 2025. Gross margin improved sequentially in 2025 to 67.4% in Q3. Net loss narrowed to $2.3 million (or $(0.09) per share). Adjusted EBITDA was positive $1.7 million. Cash and cash equivalents totaled $24.9 million at September 30, 2025. Management hosted a conference call on November 12, 2025 to discuss results and recent clinical and commercial highlights.
Journey Medical (Nasdaq: DERM) will release third quarter 2025 financial results after U.S. markets close on Wednesday, November 12, 2025. Management will host a conference call and live audio webcast the same day at 4:30 p.m. ET to discuss results and provide a corporate update.
Domestic dial-in is 1-866-777-2509, international dial-in is 1-412-317-5413. Participants may register at the provided registration link and a live webcast will be available on the Investors > News and Events page with replay accessible for approximately 30 days.
Journey Medical (Nasdaq: DERM) presented pooled Phase 3 efficacy data for Emrosi (DFD-29) at the 2025 Fall Clinical Dermatology Conference on October 24, 2025. The pooled analysis of MVOR-1 and MVOR-2 included 653 subjects randomized 3:3:2 and compared once-daily DFD-29, Oracea (doxycycline 40 mg) and placebo over 16 weeks.
Key results: IGA success 62.7% for DFD-29 vs 39.0% for Oracea and 28.2% for placebo (P<0.001 each). Mean inflammatory lesion change at week 16: -19.2 for DFD-29 vs -14.8 Oracea and -11.3 placebo (P<0.001 each). The company reported no major safety issues or serious adverse events related to study drug.
Journey Medical (Nasdaq: DERM) said its management team will participate in two investor conferences in October 2025 in New York City.
Events and formats:
- ROTH Healthcare Opportunities Conference — Thursday, October 9, 2025 — 1x1 meetings.
- The ThinkEquity Conference — Thursday, October 30, 2025 — presentation and 1x1 meetings.
The company will engage investors through one-on-one meetings and a public presentation on the listed dates.
Journey Medical Corporation (NASDAQ:DERM), a commercial-stage pharmaceutical company focused on marketing FDA-approved dermatological treatments, has announced its participation in two upcoming investor conferences in September 2025.
CEO Claude Maraoui will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 8, participating in a fireside chat and one-on-one meetings. Additionally, the company will participate in the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference on September 11, featuring one-on-one meetings with investors.
Journey Medical Corporation (NASDAQ:DERM), a commercial-stage pharmaceutical company focused on FDA-approved dermatological treatments, announced its upcoming presentation at the Emerging Growth Conference. Claude Maraoui, Co-Founder, President and CEO, will deliver a corporate overview on August 20, 2025, at 12:35 p.m. ET.
The presentation will be conducted virtually through video webcasts. Investors can access the live event by registering at emerginggrowth.com/conference, and an archived version will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel.
Journey Medical Corporation (NASDAQ:DERM) reported Q2 2025 financial results with total revenues of $15.0 million, including $2.8 million from Emrosi™ in its first full quarter of sales. The company achieved a 67% gross margin, up from 61% in the prior year quarter, despite reporting a net loss of $3.8 million or $(0.16) per share.
Key highlights include Emrosi's expanded payer access covering over 100 million commercial lives in the U.S., up from 54 million in May 2025. The company joined the Russell 2000® and Russell 3000® Indexes in June 2025. Journey Medical maintained its cash position at $20.3 million as of June 30, 2025, and appointed Ramsey Alloush as Chief Operating Officer.
Journey Medical Corporation (NASDAQ:DERM) announced that its management team will ring the Nasdaq MarketSite closing bell on August 11, 2025, celebrating its 4-year anniversary as a public company and the commercial launch of Emrosi™, their new rosacea treatment.
CEO Claude Maraoui highlighted the company's consistent execution of its commercial strategy, led by their experienced management and specialized dermatology sales force. The company expects positive EBITDA later in 2025, citing strong initial revenue from Emrosi, improving margins, and a solid cash position.
Journey Medical Corporation (NASDAQ:DERM), a commercial-stage pharmaceutical company focused on FDA-approved dermatological treatments, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, after market close.
The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. U.S. participants can dial 1-866-777-2509, while international callers should use 1-412-317-5413. The webcast will be available on Journey Medical's website for approximately 30 days following the call.
Journey Medical Corporation (NASDAQ:DERM) announced significant expansion in commercial payer coverage for Emrosi™, its FDA-approved treatment for inflammatory rosacea lesions in adults. The coverage has increased to 65% of commercial lives (187 million) in the United States, up substantially from 29% in May 2025.
The expanded coverage is attributed to Journey Medical's targeted contracting strategy, increasing prescription demand, and strong clinical data showing Emrosi's superior efficacy over current standard treatments. The medication is available through specialty pharmacy chains, with the company positioning it to become the standard of care for rosacea treatment.
FAQ
What is the current stock price of Journey Medical (DERM)?
What is the market cap of Journey Medical (DERM)?
